Skip to main content
Log in

Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty

  • Original Paper
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to assess the effects of N-acetylcysteine (N-ACC) on contrast-induced nephropathy (CIN) defined by Cystatin C (Cys-C) serum levels and to evaluate the influence of Cys-C on clinical outcome in patients with ST-elevation myocardial infarction (STEMI).

Methods

In total, 251 patients with STEMI undergoing primary percutaneous coronary intervention (PCI) were randomized to either high-dose N-ACC (2 × 1200 mg/d for 48 h) with optimal hydration or placebo plus optimal hydration. Serum Cys-C was measured at baseline, immediately, 24, 48 and 72 h after PCI. CIN was defined as an increase in serum Cys-C levels of 25% or more from baseline within 72 h after PCI. Major adverse cardiac events (MACE)—defined as death, recurrent infarction and congestive heart failure—within 6 months were recorded.

Results

Baseline Cys-C was 1294 ± 611 and 1352 ± 811 ng/mL (p = 0.54) for the N-ACC and placebo group, respectively. There was a steady increase in Cys-C in both groups within the first 72 h after randomization. CIN occurred in 74.6 and in 70.4% of patients in the N-ACC and placebo group, respectively (p = 0.46). The magnitude of increase in the serum concentration of Cys-C was an independent predictor for MACE after 6 months of follow-up.

Conclusions

High-dose N-ACC does not provide additional benefit over placebo with respect to Cys-C defined CIN in STEMI patients undergoing primary PCI. The magnitude of increase in Cys-C serum levels in the early course after STEMI is a predictor of medium-term MACE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr (2002) Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105(19):2259–2264. doi:10.1161/01.CIR.0000016043.87291.33

    Article  PubMed  Google Scholar 

  2. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD (2003) Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 108(22):2769–2775. doi:10.1161/01.CIR.0000103623.63687.21

    Article  PubMed  Google Scholar 

  3. Wickenbrock I, Perings C, Maagh P, Quack I, van Bracht M, Prull MW, Plehn G, Trappe HJ, Meissner A (2009) Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 98(12):765–772. doi:10.1007/s00392-009-0058-5

    Article  PubMed  Google Scholar 

  4. Chong E, Poh KK, Liang S, Soon CY, Tan HC (2010) Comparison of risks and clinical predictors of contrast-induced nephropathy in patients undergoing emergency versus nonemergency percutaneous coronary interventions. J Interv Cardiol 23(5):451–459. doi:10.1111/j.1540-8183.2010.00581.x

    Article  PubMed  Google Scholar 

  5. Bagshaw SM, Ghali WA (2004) Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2:38. doi:10.1186/1741-7015-2-38

    Article  PubMed  Google Scholar 

  6. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ (2003) A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41(12):2114–2118. doi:10.1016/S0735-1097(03)00487-X

    Article  PubMed  Google Scholar 

  7. Briguori C, Colombo A, Violante A, Balestrieri P, Manganelli F, Paolo Elia P, Golia B, Lepore S, Riviezzo G, Scarpato P, Focaccio A, Librera M, Bonizzoni E, Ricciardelli B (2004) Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25(3):206–211. doi:10.1016/j.ehj.2003.11.016

    Article  PubMed  CAS  Google Scholar 

  8. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL (2007) A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 5:32. doi:10.1186/1741-7015-5-32

    Article  PubMed  Google Scholar 

  9. Tepel M, Aspelin P, Lameire N (2006) Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 113(14):1799–1806. doi:10.1161/CIRCULATIONAHA.105.595090

    Article  PubMed  Google Scholar 

  10. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W (2000) Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343(3):180–184. doi:10.1056/NEJM200007203430304

    Article  PubMed  CAS  Google Scholar 

  11. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, Desch S, Gutberlet M, Schuler G (2010) Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention The LIPSIA-N-ACC (prospective, single-blind, placebo-controlled, randomized leipzig Immediate percutaneous coronary intervention acute myocardial infarction N-ACC) trial. J Am Coll Cardiol 55(20):2201–2209. doi:10.1016/j.jacc.2009.08.091

    Article  PubMed  CAS  Google Scholar 

  12. Scheller B (2007) How to protect from contrast media-induced nephropathy? Clin Res Cardiol 96(3):125–129. doi:10.1007/s00392-007-0486-z

    Article  PubMed  CAS  Google Scholar 

  13. Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, Breithardt G, Hense HW, Schaefer RM (2007) A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the dialysis-versus-diuresis (DVD) Trial. Clin Res Cardiol 96(3):130–139. doi:10.1007/s00392-007-0473-4

    Article  PubMed  CAS  Google Scholar 

  14. Grubb AO (2000) Cystatin C—properties and use as diagnostic marker. Adv Clin Chem 35:63–99. doi:10.1016/S0065-2423(01)35015-1

    Article  PubMed  CAS  Google Scholar 

  15. Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40(2):221–226. doi:10.1053/ajkd.2002.34487

    Article  PubMed  CAS  Google Scholar 

  16. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int 66(3):1115–1122. doi:10.1111/j.1523-1755.2004.00861.x

    Article  PubMed  CAS  Google Scholar 

  17. Newman DJ, Thakkar H, Edwards RG, Wilkie M, White T, Grubb AO, Price CP (1995) Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 47(1):312–318. doi:10.1038/ki.1995.40

    Article  PubMed  CAS  Google Scholar 

  18. Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, Riesen W, Wuthrich RP (2004) Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 61(2):98–102

    PubMed  CAS  Google Scholar 

  19. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS (2006) Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145(4):237–246 pii: 145/4/237

    PubMed  CAS  Google Scholar 

  20. Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ (2009) Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 104(3):389–392. doi:10.1016/j.amjcard.2009.03.059

    Article  PubMed  CAS  Google Scholar 

  21. Deo R, Shlipak MG, Ix JH, Ali S, Schiller NB, Whooley MA (2009) Association of cystatin C with ischemia in patients with coronary heart disease. Clin Cardiol 32(11):E18–E22. doi:10.1002/clc.20465

    Article  PubMed  Google Scholar 

  22. Ge C, Ren F, Lu S, Ji F, Chen X, Wu X (2009) Clinical prognostic significance of plasma cystatin C levels among patients with acute coronary syndrome. Clin Cardiol 32(11):644–648. doi:10.1002/clc.20672

    Article  PubMed  Google Scholar 

  23. Hoke M, Amighi J, Mlekusch W, Schlager O, Exner M, Sabeti S, Dick P, Koppensteiner R, Minar E, Rumpold H, Wagner O, Schillinger M (2010) Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke 41(4):674–679. doi:10.1161/STROKEAHA.109.573162

    Article  PubMed  CAS  Google Scholar 

  24. Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115(2):173–179. doi:10.1161/CIRCULATIONAHA.106.644286

    Article  PubMed  CAS  Google Scholar 

  25. Keller T, Messow CM, Lubos E, Nicaud V, Wild PS, Rupprecht HJ, Bickel C, Tzikas S, Peetz D, Lackner KJ, Tiret L, Munzel TF, Blankenberg S, Schnabel RB (2009) Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: results from the AtheroGene study. Eur Heart J 30(3):314–320. doi:10.1093/eurheartj/ehn598

    Article  PubMed  CAS  Google Scholar 

  26. Kilic T, Oner G, Ural E, Yumuk Z, Sahin T, Bildirici U, Acar E, Celikyurt U, Kozdag G, Ural D (2009) Comparison of the long-term prognostic value of cystatin C to other indicators of renal function, markers of inflammation and systolic dysfunction among patients with acute coronary syndrome. Atherosclerosis 207(2):552–558. doi:10.1016/j.atherosclerosis.2009.05.015

    Article  PubMed  CAS  Google Scholar 

  27. Manzano-Fernandez S, Boronat-Garcia M, Albaladejo-Oton MD, Pastor P, Garrido IP, Pastor-Perez FJ, Martinez-Hernandez P, Valdes M, Pascual-Figal DA (2009) Complementary prognostic value of cystatin C, N-terminal pro-B-type natriuretic Peptide and cardiac troponin T in patients with acute heart failure. Am J Cardiol 103(12):1753–1759. doi:10.1016/j.amjcard.2009.02.029

    Article  PubMed  CAS  Google Scholar 

  28. Sekizuka H, Akashi YJ, Kawasaki K, Yamauchi M, Musha H (2009) Cystatin C: a better marker to detect coronary artery sclerosis. J Cardiol 54(3):359–367. doi:10.1016/j.jjcc.2009.06.003

    Article  PubMed  Google Scholar 

  29. Taglieri N, Koenig W, Kaski JC (2009) Cystatin C and cardiovascular risk. Clin Chem 55(11):1932–1943. doi:10.1373/clinchem.2009.128397

    Article  PubMed  CAS  Google Scholar 

  30. Thiele H, Schindler K, Friedenberger J, Eitel I, Furnau G, Grebe E, Erbs S, Linke A, Mobius-Winkler S, Kivelitz D, Schuler G (2008) Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118(1):49–57. doi:10.1161/CIRCULATIONAHA.107.747642

    Article  PubMed  CAS  Google Scholar 

  31. Kim BJ, Sung KC, Kim BS, Kang JH, Lee KB, Kim H, Lee MH (2010) Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial. Int J Cardiol 138(3):239–245. doi:10.1016/j.ijcard.2008.08.013

    Article  PubMed  Google Scholar 

  32. Poletti PA, Saudan P, Platon A, Mermillod B, Sautter AM, Vermeulen B, Sarasin FP, Becker CD, Martin PY (2007) I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189(3):687–692. doi:10.2214/AJR.07.2356

    Article  PubMed  Google Scholar 

  33. Levey AS, Perrone RD, Madias NE (1988) Serum creatinine and renal function. Annu Rev Med 39:465–490. doi:10.1146/annurev.me.39.020188.002341

    Article  PubMed  CAS  Google Scholar 

  34. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38(10):1933–1953

    PubMed  CAS  Google Scholar 

  35. Shemesh O, Golbetz H, Kriss JP, Myers BD (1985) Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 28(5):830–838. doi:10.1038/ki.1985.205

    Article  PubMed  CAS  Google Scholar 

  36. Hoste EA, Damen J, Vanholder RC, Lameire NH, Delanghe JR, Van den Hauwe K, Colardyn FA (2005) Assessment of renal function in recently admitted critically ill patients with normal serum creatinine. Nephrol Dial Transplant 20(4):747–753. doi:10.1093/ndt/gfh707

    Article  PubMed  CAS  Google Scholar 

  37. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK (2004) The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15(2):407–410. doi:10.1097/01.ASN.0000106780.14856.55

    Article  PubMed  CAS  Google Scholar 

  38. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, Castaldo D, De Micco F, Ricciardelli B, Colombo A (2010) Cystatin C and contrast-induced acute kidney injury. Circulation 121(19):2117–2122. doi:10.1161/CIRCULATIONAHA.109.919639

    Article  PubMed  CAS  Google Scholar 

  39. Niccoli G, Conte M, Della Bona R, Altamura L, Siviglia M, Dato I, Ferrante G, Leone AM, Porto I, Burzotta F, Brugaletta S, Biasucci LM, Crea F (2008) Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. Atherosclerosis 198(2):373–380. doi:10.1016/j.atherosclerosis.2007.09.022

    Article  PubMed  CAS  Google Scholar 

  40. Koenig W, Twardella D, Brenner H, Rothenbacher D (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51(2):321–327. doi:10.1373/clinchem.2004.041889

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Holger Thiele.

Additional information

M. Droppa and S. Desch contributed equally to this manuscript.

Senior authors, V. Adams and H. Thiele, contributed equally to this manuscript.

http://www.ClinicalTrials.gov: NCT00463749

Rights and permissions

Reprints and permissions

About this article

Cite this article

Droppa, M., Desch, S., Blase, P. et al. Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol 100, 1037–1043 (2011). https://doi.org/10.1007/s00392-011-0338-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-011-0338-8

Keywords

Navigation